Recent 8-K filings for COGT
Highest-materiality recent filing
Cogent: bezuclastinib combo reduces progression risk by 50% in Phase 3 GIST trial
- PEAK trial met primary endpoint: HR 0.50 (95% CI: 0.39–0.65) for progression-free survival.
- Median PFS 16.5 months (bezuclastinib + sunitinib) vs 9.2 months (sunitinib alone).
-
Cogent Biosciences launches $400M at-the-market equity offering via Guggenheim
Filed prospectus supplement on Aug 10, 2026 to sell up to $400M of common stock under ATM sales agreement with Guggenheim Securities.
-
Cogent reports Q2 net loss $96.4M; bezuclastinib PDUFA dates set for Nov/Dec 2026
Net loss $96.4M vs $73.5M in Q2 2025; R&D $70.8M, G&A $31.8M.
-
Net loss $97.4M for Q1 2026 vs $72.0M Q1 2025; R&D spend $75.4M, G&A $28.2M.
-
Cogent Biosciences reports Q4/FY2025 results; advances bezuclastinib NDAs in SM and GIST
SUMMIT NDA for bezuclastinib in NonAdvSM submitted Dec 2025; APEX NDA for AdvSM on track for 1H 2026.
-
Cogent reports positive SUMMIT and APEX trial results for bezuclastinib in mastocytosis
SUMMIT Part 2: mean TSS change -24.3 (-43%) vs placebo -15.4 (-29%), p<0.001; 34.3% vs 18.1% had >=50% TSS reduction (p=0.01).
-
Cogent completes $230M 1.625% convertible senior notes offering due 2031
Aggregate principal $230M including full exercise of $30M over-allotment option by underwriters.
-
Equity offering of 9,677,420 shares at $31.00 per share, upsized from $200M, with underwriters exercising over-allotment for additional 1,451,613 shares.
-
Cogent: bezuclastinib combo reduces progression risk by 50% in Phase 3 GIST trial
PEAK trial met primary endpoint: HR 0.50 (95% CI: 0.39–0.65) for progression-free survival.
-
Cogent Biosciences reports Q3 net loss $80.9M; cash $390.9M; PEAK, APEX readouts in Nov/Dec 2025
Cash, cash equivalents and marketable securities at $390.9M; pro forma cash $430M expected to fund into 2027.
-
Cogent reports positive SUMMIT trial, Q2 net loss $73.5M; pro-forma cash $453M
SUMMIT trial met primary endpoint: TSS improvement 8.91 points vs placebo (p=0.0002); 87.4% bezuclastinib patients had ≥50% tryptase reduction.
-
Bezuclastinib SUMMIT trial beats all primary/secondary endpoints; NDA submission by end 2025
SUMMIT trial met primary endpoint: mean TSS reduction of 24.3 vs 15.4 placebo (p=0.0002); 8.91-point placebo-adjusted improvement.
-
SUMMIT Part 2 met primary endpoint with highly significant mean TSS reduction of 24.3 points vs placebo 15.4 (p=0.0002) at 24 weeks.
-
Cogent Biosciences secures up to $400M non-dilutive debt facility; $50M drawn at closing
$400M credit facility from SLR; first tranche of $50M funded on June 11, 2025.
-
Cogent Biosciences Q1 net loss $72M; cash $245.7M; SUMMIT readout in July
Net loss $72.0M vs $58.3M YoY; R&D spend $63.0M (+20% YoY) driven by ongoing trials.
-
Cogent Biosciences Q4/FY2024 net loss $67.9M/$255.9M; SUMMIT results due July 2025
Net loss Q4 $67.9M, FY $255.9M (vs $54.4M and $192.4M); R&D spend $62M/$232.7M.
-
Cogent Biosciences reports positive Phase 2 bezuclastinib data in AdvSM and NonAdvSM at ASH 2024
APEX (AdvSM): 52% ORR per mIWG-MRT-ECNM; 61% in TKI-naïve; 83% at 100 mg BID. Median PFS not reached; 24-mo PFS rate 82%.
-
Cogent Q3 net loss $70.6M; PEAK trial enrolls 413 patients, top-line data in 2025
Net loss $70.6M in Q3 2024 vs $55.4M in Q3 2023; cash $345.5M sufficient into late 2026.
-
Cogent Biosciences completes PEAK trial enrollment and advances past interim futility analysis
Phase 3 PEAK trial enrolled 413 GIST patients, exceeding target; top-line results expected by end of 2025.
-
Cash, cash equivalents and marketable securities $389.9M as of June 30, 2024; expected to fund operations into 2027.
-
Cogent reaches FDA alignment on MS2D2 endpoint for SUMMIT trial; enrollment timeline reaffirmed
FDA alignment on novel patient-reported outcome measure MS2D2 for Part 2 of SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM).
-
Cogent Biosciences reports Q4/FY2023 net loss; $487M pro-forma cash; bezuclastinib trials on track
Q4 2023 net loss $54.4M; FY2023 net loss $192.4M (up from $140.2M YoY); R&D expenses $173.8M for 2023.
-
Cogent Biosciences raises $225M in oversubscribed PIPE at $7.50/share, 37% premium
Gross proceeds of $225M from 17.7M common shares at $7.50 and Series B convertible preferred.
-
Cogent reports positive Phase 2 bezuclastinib data in systemic mastocytosis at ASH 2023
SUMMIT Part 1a: 100% of bezuclastinib patients achieved ≥50% reduction in serum tryptase vs 0% on placebo; 100% achieved ≥50% reduction in KIT D816V VAF.
-
Cogent Biosciences Q3 net loss $55.4M; cash $312.8M providing runway into 2026
Net loss of $55.4M for Q3 2023 vs $35.1M in Q3 2022; R&D expenses $50.1M (up 67% YoY).
-
Cogent Q2 net loss $44.1M, cash $350.9M, PEAK DCR 55%, FGFR2 candidate nominated
Cash & equivalents $350.9M at June 30 (up from $220.3M on Mar 31); funded into 2026.
-
Cogent Biosciences prices $150M common stock offering of 12.5M shares at $12.00/share
Offers 12,500,000 shares of common stock at $12.00 per share; gross proceeds ~$150M.
-
Cogent Biosciences reports positive Phase 3 PEAK lead-in data for bezuclastinib in GIST
39 patients treated; 55% disease control rate across efficacy-evaluable patients in Part 1.
-
Net loss $39.6M Q4, $140.2M FY2022 vs $72.3M FY2021; R&D expenses $121.6M FY2022.
-
Cogent Biosciences reports 89% ORR in TKI-naive AdvSM patients from Phase 2 APEX trial
89% ORR in TKI-naïve patients; 73% ORR in all evaluable patients (median 27-week follow-up).
-
Cogent Biosciences Q3 net loss $35.1M; cash $289.1M, runway into 2025; Phase 3 PEAK trial started
Net loss $35.1M vs $19.1M YoY; R&D expense $29.9M (up from $14.8M) due to trials and team expansion.
-
Cogent Biosciences Q2 net loss $34.9M; cash $325.6M after June public offering
Cash and equivalents $325.6M at June 30, 2022, up from $191M at March 31, 2022; includes $172.6M from June 2022 public offering, funds operations into 2025.
-
Cogent closes upsized $172.6M public offering of common stock and pre-funded warrants
Gross proceeds ~$172.6M from 17,899,698 shares at $8.25 and 3,030,302 pre-funded warrants at $8.24.
-
Offering of 15,169,698 shares at $8.25 per share plus pre-funded warrants for 3,030,302 shares at $8.24.
-
All 11 patients achieved ≥50% serum tryptase reduction; median reduction 89%.
-
Cogent Biosciences Q4/FY2021 net loss $24.9M/$72.3M; three bezuclastinib trials enrolling
Cash $219.7M at Dec 31, 2021, sufficient to fund operations into 2024.
-
Cogent Biosciences Q3 net loss $19.1M; initiates SUMMIT Phase 2, cash $202.9M
Net loss of $19.1M in Q3 2021 vs $50.0M in Q3 2020 (prior included $46.9M asset acquisition charge).
-
Net loss of $16.5M for Q2 2021 vs $7.4M in Q2 2020; R&D spend $12.4M, G&A $4.9M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.95 · Median 0.68 · Most common event other_material